<DOC>
	<DOCNO>NCT00844623</DOCNO>
	<brief_summary>The purpose study determine whether activation prodrug intratumoral gene transfer safe human , determine dose level clinical development .</brief_summary>
	<brief_title>TK-based Suicide Gene Therapy Hepatocellular Carcinoma</brief_title>
	<detailed_description>The study phase I clinical trial evaluate intratumoral injection defective adenovirus contain HSVtk ( thymidine kinase herpes simplex virus ) , patient advance hepatocellular carcinoma amenable curative therapy . The study conduct single center Spain . Five consecutive cohort two patient receive increase dos vector intratumoral injection equal dose either intravenous ganciclovir oral valganciclovir . The dose received consecutive cohort patient progressively higher accord prefixed scale .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Unequivocal diagnosis hepatocellular carcinoma accord histological confirmation EASLAASLD criterion Contraindication surgical treatment disease Detectable disease image Ability give inform consent express willingness fulfill protocol requirement study Current pregnancy breastfeed Acute infection Positive antiHIV antibody Hematologic alteration attributable hypersplenism , case , intense neutropenia thrombocytopenia , define neutrophil count lower 0,5/pL platelet count low 20/pL Participation clinical trial previous month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>primary liver cancer , hepatoma</keyword>
</DOC>